Inhibrx to Present Topline Results from Registrational Chondrosarcoma Trial of Ozekibart
核心洞察
Inhibrx Biosciences will host a webcast on October 23, 2025, to present topline results from the registrational ChonDRAgon study of ozekibart in advanced chondrosarcoma (搜索) patients.
The Phase 2 trial evaluates ozekibart as a single agent versus placebo in patients with metastatic or unresectable conventional chondrosarcoma (搜索).
The company will also provide updates on expansion trials investigating ozekibart combinations in colorectal cancer (搜索) and Ewing sarcoma (搜索).
Inhibrx Biosciences announced it will present topline results from its registrational ChonDRAgon study investigating ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma (搜索) during a live webcast on October 23, 2025, at 1:30 p.m. Pacific Time. The San Diego-based clinical-stage biopharmaceutical company will also provide updates on ongoing expansion trials evaluating ozekibart in combination therapies for colorectal cancer (搜索) and Ewing sarcoma (搜索).
Registrational Trial Design and Regulatory Status
The ChonDRAgon study represents a randomized, blinded, placebo-controlled, registration-enabling Phase 2 trial that Inhibrx initiated in June 2021. The trial evaluates ozekibart as a single agent versus placebo in patients with metastatic, unresectable conventional chondrosarcoma (搜索), a rare bone cancer with limited treatment options.
Ozekibart has received significant regulatory recognition for this indication. In January 2021, the FDA granted Fast Track designation to ozekibart for treating patients with metastatic or unresectable conventional chondrosarcoma (搜索). The agency further granted orphan drug designation to ozekibart for chondrosarcoma in November 2021, providing potential market exclusivity benefits upon approval.
Mechanism of Action and Drug Development
Ozekibart is a precision-engineered, tetravalent death receptor 5 (搜索) (DR5 (搜索)) agonist antibody designed to exploit tumor-biased cell death induced by DR5 activation. The drug utilizes multivalent formats where precise valency can be optimized in a target-centric manner to mediate appropriate agonist function, according to the company.
Beyond the chondrosarcoma (搜索) program, Inhibrx is investigating ozekibart in Phase 1/2 trials across multiple tumor types. The company is evaluating the drug in combination with FOLFIRI (搜索) for late-line colorectal cancer (搜索) and in combination with irinotecan and temozolomide for refractory Ewing sarcoma (搜索).
Company Background and Pipeline
Inhibrx Biosciences operates as a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates for oncology and rare diseases. The company was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc., following a series of corporate restructuring transactions.
The company's current clinical pipeline includes ozekibart and INBRX-106, both utilizing multivalent formats optimized for target-specific agonist function. Inhibrx Biosciences utilizes diverse protein engineering methods to address complex target and disease biology requirements through its proprietary protein engineering platforms.
Webcast Access and Availability
Investors can access the presentation via web at https://app.webinar.net/RdZmlEPaEyw or by dialing 1-888-880-3330 with conference ID 9577647. The webcast will remain available for 60 days following the event through the investors section of Inhibrx's website. Following the presentation, the company plans to update its corporate presentation materials on its website.